A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancie
about
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian DataEffect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo.A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Clinical utility of targeted treatments in the management of epithelial ovarian cancer.Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.Protein kinase C, an elusive therapeutic target?Network analysis identifies an HSP90-central hub susceptible in ovarian cancerPathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Clinical trials and future potential of targeted therapy for ovarian cancer.Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Clinical trials in gynecologic oncology: Past, present, and future.Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).
P2860
Q30414010-C69B5EC8-280D-4762-8E16-5271FD0EEE89Q30842944-D4602F3B-CA0C-41DF-A2AE-C89EAD6BEA98Q33460375-1160137D-36F3-4C59-B784-8BA3195A878AQ35747034-48632A81-23A1-42BF-893F-799531C14C40Q35913613-D1666C61-C8E5-47AC-BE9B-C8B08E42638FQ36171268-B1523016-08F3-49ED-9C06-84D8766BA969Q36816535-98213743-335F-4627-A94A-E22120E9A5B1Q37109823-5556A867-18CD-4426-9807-1B8EE02733FFQ37141320-3F978906-76B8-48D2-8A38-262C3E93E216Q37185385-ED28C2B5-0EE2-4021-B744-8B379FB387F3Q37420213-7073E71E-5A68-4BFD-A1CD-615BA2B91D9DQ38038489-02AA2CB2-E9F2-4F8B-859F-A50D898B3911Q38115596-AA55DB15-D643-4234-B4F3-0AC457264B7EQ38198095-F2CB03EE-57D0-48D9-BEE7-DB306DA77412Q38631373-05E9E601-E101-45BD-AE68-1393B2BD7C1EQ47796770-CD95A472-A841-4333-B114-996D584C4028Q54232641-0DB5D02E-9A3E-4E73-8B61-1E56F8454E81
P2860
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancie
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@ast
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@en
type
label
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@ast
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@en
prefLabel
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@ast
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@en
P2093
P2860
P1433
P1476
A Gynecologic Oncology Group p ...... primary peritoneal malignancie
@en
P2093
Andrew K Godwin
David P Michelin
Doris M Benbrook
Jean A Hurteau
Kathleen M Darcy
Koen De Geest
Lydia Usha
Michael W Sill
Parviz Hanjani
Robert S Mannel
P2860
P304
P356
10.1016/J.YGYNO.2011.02.013
P407
P577
2011-03-17T00:00:00Z